The Treatment Landscape for Gastroesophageal Adenocarcinomas

Mohamad Bassam Sonbol, Surabhi Pathak, Tanios Bekaii-Saab

Research output: Contribution to journalArticlepeer-review


The treatment landscape for gastroesophageal adenocar-cinomas has significantly changed over the last year. The addition of nivolumab to first-line chemotherapy has led to survival benefit in patients who have metastatic gastroesophageal adenocarcino-ma with a programmed death ligand 1 combined positive score of 5 or greater. Similarly, in patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive gastroesophageal adenocarcinoma, the addition of pembrolizumab to chemotherapy and trastuzumab has significantly improved efficacy. Furthermore, a phase 2 study revealed that trastuzumab deruxtecan, a new anti-body-drug conjugate, significantly improved survival in comparison with chemotherapy among patients with HER2-positive gastric cancer in the refractory setting, and it produced a signal of efficacy in the second-line setting. Chemoimmunotherapy combinations are now considered the standard of care for a significant number of patients with gastroesophageal adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)169-177
Number of pages9
JournalClinical Advances in Hematology and Oncology
Issue number3
StatePublished - Mar 2022


  • Esophageal cancer
  • Gastric cancer
  • Gastroesophageal adenocarcinoma
  • Nivolumab
  • Pembrolizumab
  • Trastuzumab deruxtecan

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The Treatment Landscape for Gastroesophageal Adenocarcinomas'. Together they form a unique fingerprint.

Cite this